Jazz Pharmaceuticals PLC (JAZZ)
108.24
+1.14
(+1.06%)
USD |
NASDAQ |
Apr 18, 13:22
Jazz Pharmaceuticals Revenue (Quarterly): 1.012B for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.012B |
| September 30, 2023 | 972.14M |
| June 30, 2023 | 957.32M |
| March 31, 2023 | 892.81M |
| December 31, 2022 | 972.12M |
| September 30, 2022 | 940.65M |
| June 30, 2022 | 932.88M |
| March 31, 2022 | 813.72M |
| December 31, 2021 | 896.73M |
| September 30, 2021 | 838.12M |
| June 30, 2021 | 751.81M |
| March 31, 2021 | 607.58M |
| December 31, 2020 | 665.52M |
| September 30, 2020 | 600.89M |
| June 30, 2020 | 562.44M |
| March 31, 2020 | 534.73M |
| December 31, 2019 | 581.74M |
| September 30, 2019 | 537.70M |
| June 30, 2019 | 534.13M |
| March 31, 2019 | 508.19M |
| December 31, 2018 | 476.46M |
| September 30, 2018 | 469.37M |
| June 30, 2018 | 500.48M |
| March 31, 2018 | 444.61M |
| December 31, 2017 | 436.40M |
| Date | Value |
|---|---|
| September 30, 2017 | 411.86M |
| June 30, 2017 | 394.39M |
| March 31, 2017 | 376.05M |
| December 31, 2016 | 396.62M |
| September 30, 2016 | 374.18M |
| June 30, 2016 | 381.16M |
| March 31, 2016 | 336.01M |
| December 31, 2015 | 340.88M |
| September 30, 2015 | 340.87M |
| June 30, 2015 | 333.75M |
| March 31, 2015 | 309.30M |
| December 31, 2014 | 328.14M |
| September 30, 2014 | 306.58M |
| June 30, 2014 | 291.23M |
| March 31, 2014 | 246.92M |
| December 31, 2013 | 235.77M |
| September 30, 2013 | 232.16M |
| June 30, 2013 | 208.25M |
| March 31, 2013 | 196.24M |
| December 31, 2012 | 183.70M |
| September 30, 2012 | 175.52M |
| June 30, 2012 | 124.23M |
| March 31, 2012 | 102.53M |
| December 31, 2011 | 83.54M |
| September 30, 2011 | 73.29M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
534.13M
Minimum
Jun 2019
1.012B
Maximum
Dec 2023
768.68M
Average
813.72M
Median
Mar 2022
Revenue (Quarterly) Benchmarks
| Alkermes PLC | 377.48M |
| Endo International PLC | 497.73M |
| Medtronic PLC | 8.089B |
| Perrigo Co PLC | 1.157B |
| Iterum Therapeutics PLC | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 94.15M |
| Total Expenses (Quarterly) | 871.44M |
| EPS Diluted (Quarterly) | 1.42 |
| Enterprise Value | 10.76B |
| Gross Profit Margin (Quarterly) | 89.40% |
| Profit Margin (Quarterly) | 9.30% |
| Earnings Yield | 5.65% |
| Operating Earnings Yield | 7.66% |
| Normalized Earnings Yield | 5.761 |